US FDA panel votes against BrainStorm's ALS therapy

Brainstorm Cell Therapeutics

27/09/2023 23:05

Sept 27 (Reuters) - The U.S. health regulator's advisers
on Wednesday voted against BrainStorm Cell Therapeutics'
 BCLI.O  therapy for patients with amyotrophic lateral sclerosis
(ALS), a neurodegenerative disease.

 (Reporting by Mariam Sunny in Bengaluru; Editing by Shinjini
Ganguli and Shounak Dasgupta)
 ((Mariam.ESunny@thomsonreuters.com))